Circassia shares tank as cat allergy drug fails to beat placebo effect

Comments Off on Circassia shares tank as cat allergy drug fails to beat placebo effect

Investors have suffered a bad reaction to Circassia, the pharma firm behind a highly-anticipated cat allergy treatment, with its shares slumping 62% after trials showed a placebo worked just as well.

Circassia had claimed its vaccine had a large market, with 24 million Americans alone allergic to cats.

So the shares tanked 169.2p to 101.2p when it admitted late-stage trials showed a placebo “greatly, and equally, reduced subjects’ symptoms”.

It was that potential vaccine that helped Circassia become the UK’s largest biotech market listing in more than a decade in 2014 and raise a further £275 million last year.

But chief executive Steve Harris said Circassia would have to “address the implications” for its other projects, admitting it had pulled the plug on a hay fever treatment and a ragweed allergy medicine. 

Imperial Innovations, with a 9.3% stake in Circassia, was also injured by the news: its shares fell 7% to 403.9p. Imperial backer Neil Woodford also lost out.

<!– –>

Source Article from http://www.standard.co.uk/business/circassia-shares-tank-as-cat-allergy-drug-fails-to-beat-placebo-effect-a3276156.html

June 20, 2016 |
Copyright © 2018 LondonBusinessLink.co.uk. All Rights Reserved. LondonBusinessLink.co.uk
WordPress Directory Theme

Classified Ads Software

We use cookies to ensure that we give you the best experience on our website.
More about our cookies
Ok
Skip to toolbar